{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:13:55Z","timestamp":1789992835676,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.14283\/jpad.2020.24","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T17:15:06Z","timestamp":1614273306000},"page":"146-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["The Future of Anti-Amyloid Trials"],"prefix":"10.1016","volume":"7","author":[{"given":"P.S.","family":"Aisen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Doody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Salloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"Selkoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Vellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.14283\/jpad.2020.24_bib1","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease","volume":"380","author":"Egan","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.14283\/jpad.2020.24_bib2","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMc1813435","article-title":"Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease","volume":"380","author":"Henley","year":"2019","journal-title":"N Engl J Med"},{"key":"10.14283\/jpad.2020.24_bib3","article-title":"Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials","author":"Wessels","year":"2019","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.14283\/jpad.2020.24_bib4","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1080\/14737175.2018.1531706","article-title":"BACE inhibitors in clinical development for the treatment of Alzheimer's disease","volume":"18","author":"Panza","year":"2018","journal-title":"Expert Rev Neurother"},{"issue":"21","key":"10.14283\/jpad.2020.24_bib5","doi-asserted-by":"crossref","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"10.14283\/jpad.2020.24_bib6","doi-asserted-by":"crossref","first-page":"560","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"7618","key":"10.14283\/jpad.2020.24_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.14283\/jpad.2020.24_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"10.14283\/jpad.2020.24_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jalz.2011.09.224","article-title":"Safety and biomarker effects of solanezumab in patients with Alzheimer's disease","volume":"8","author":"Farlow","year":"2012","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.14283\/jpad.2020.24_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.14283\/jpad.2020.24_bib11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jalz.2015.06.1893","article-title":"Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients","volume":"12","author":"Siemers","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.14283\/jpad.2020.24_bib12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"key":"10.14283\/jpad.2020.24_bib13","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.trci.2019.05.007","article-title":"Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease","volume":"5","author":"Schwarz","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"10.14283\/jpad.2020.24_bib14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-Amyloid-\u03b2 Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol Psychiatry"},{"issue":"1","key":"10.14283\/jpad.2020.24_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2020.24_bib16","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.trci.2018.10.001","article-title":"Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia","volume":"4","author":"Willis","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"issue":"3","key":"10.14283\/jpad.2020.24_bib17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.25410","article-title":"Amyloid-\u03b2 immunotherapy for alzheimer disease: Is it now a long shot?","volume":"85","author":"Panza","year":"2019","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.14283\/jpad.2020.24_bib18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2020.24_bib19","article-title":"The role of futility analyses in AD clinical trials","volume":"7","author":"Doody","year":"2020","journal-title":"J Prev Alz Dis"},{"issue":"3","key":"10.14283\/jpad.2020.24_bib20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.14283\/jpad.2019.23","article-title":"Editorial: Failure After Failure. What Next in AD Drug Development?","volume":"6","author":"Aisen","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.14283\/jpad.2020.24_bib21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13041-019-0448-1","article-title":"Blood-based molecular biomarkers for Alzheimer's disease","volume":"12","author":"Zetterberg","year":"2019","journal-title":"Molecular Brain"},{"issue":"3","key":"10.14283\/jpad.2020.24_bib22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.14283\/jpad.2019.12","article-title":"Combination Therapy for Alzheimer's Disease: Perspectives of the EU\/US CTAD Task Force","volume":"6","author":"Gauthier","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"10.14283\/jpad.2020.24_bib23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.14283\/jpad.2019.14","article-title":"Anti-Tau Trials for Alzheimer's Disease: A Report from the EU\/US\/CTAD Task Force","volume":"6","author":"Cummings","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.14283\/jpad.2020.24_bib24","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.1038\/s41467-019-12921-z","article-title":"Tau deposition is associated with functional isolation of the hippocampus in aging","volume":"10","author":"Harrison","year":"2019","journal-title":"Nat Commun"},{"issue":"6","key":"10.14283\/jpad.2020.24_bib25","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/brain\/awz090","article-title":"A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia","volume":"142","author":"Pontecorvo","year":"2019","journal-title":"Brain"},{"issue":"3","key":"10.14283\/jpad.2020.24_bib26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jalz.2018.09.010","article-title":"Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease","volume":"15","author":"Chen","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.14283\/jpad.2020.24_bib27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.14283\/jpad.2018.23","article-title":"What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force","volume":"5","author":"Aisen","year":"2018","journal-title":"J Prev Alzheimers Dis"},{"issue":"111","key":"10.14283\/jpad.2020.24_bib28","doi-asserted-by":"crossref","first-page":"111c","DOI":"10.1126\/scitranslmed.3002609","article-title":"Testing the right target and right drug at the right stage","volume":"3","author":"Sperling","year":"2011","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.14283\/jpad.2020.24_bib29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","article-title":"The DIAN-TU Next Generation Alzheimer's prevention trial: adaptive design and disease progression model","volume":"13","author":"Bateman","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2020.24_bib30","author":"Sierra"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724004369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724004369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:12:58Z","timestamp":1737339178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724004369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S2274580724004369"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2020.24","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Future of Anti-Amyloid Trials","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2020.24","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}